Levetiracetam

CHEMBL1286 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
170.2 g/mol
LogP
-0.3
Phase
4

An anticonvulsant used to treat focal and generalized seizures in epilepsy, and studied for mood stabilization in bipolar disorder. It works through a unique mechanism involving synaptic vesicle protein 2A (SV2A) to reduce abnormal neuronal activity.

Khối lượng phân tử

170,2100 g/mol

LogP

-0,30

TPSA

63,40 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Cơ chế tác dụng

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of …

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC[C@@H](C(N)=O)N1CCCC1=O

InChI

InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1

Molecular Formula

C8H14N2O2

HBD / HBA

1 / 2

Liên kết có thể quay

3

Nguyên tử nặng

12

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

An anticonvulsant used to treat focal and generalized seizures in epilepsy, and studied for mood stabilization in bipolar disorder. It works through a unique mechanism involving synaptic vesicle protein 2A (SV2A) to reduce abnormal neuronal activity.

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Yes, Levetiracetam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1286. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5284583. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.